Form 4: CEO Acquires $20K Convertible Note in Provectus Biopharma

Provectus Biopharmaceuticals' CEO, Edward Pershing, acquired an 8% unsecured convertible promissory note valued at $20,000, convertible into Series D-1 Preferred Stock.

Summary

• Edward Pershing, CEO and Director of Provectus Biopharmaceuticals, Inc. (PVCT), acquired an 8% unsecured convertible promissory note on October 23, 2025.
• The note has a principal amount of $20,000 and is convertible into Series D-1 Convertible Preferred Stock at a price of $2.862 per share.
• This conversion equates to approximately 6,989 shares of Series D-1 Preferred Stock.
• Each share of Series D-1 Preferred Stock is further convertible into 10 shares of the Issuer's common stock, potentially leading to 69,890 shares of common stock.
• The note was issued as part of the Issuer's 2025 Financing.
• The note automatically converts to Series D-1 Preferred Stock on October 23, 2026, which is twelve months after its issue date.
• Series D-1 Preferred Stock automatically converts into Common Stock on June 26, 2026, unless converted earlier.

Sentiment

Score: 7

Explanation: The acquisition of a convertible note by the CEO is a positive indicator of insider confidence and commitment to the company's future, despite the potential for future dilution.

Positives

• The CEO's acquisition of a convertible note signals management's confidence in the company's future prospects.
• The transaction is part of the company's 2025 Financing, indicating ongoing efforts to secure capital.

Negatives

• No explicit negatives are detailed in the filing regarding the transaction itself.

Risks

• The conversion of the note into Series D-1 Preferred Stock and subsequently into common stock will result in dilution for existing common shareholders.
• The potential issuance of 69,890 new common shares upon full conversion could impact the per-share value and voting power of current shareholders.

Future Outlook

The convertible note provides a future pathway for the CEO's investment to convert into equity, aligning management's interests with shareholders. The staggered conversion dates for the note and the preferred stock indicate a structured approach to future equity issuance.

Management Comments

• Edward Pershing, as CEO, acquired the convertible note, demonstrating a direct investment in the company's future.

Industry Context

In the biotechnology sector, companies often utilize convertible notes and preferred stock as financing mechanisms to raise capital, especially for research and development-intensive operations. Insider participation in such financings can be viewed positively by the market, indicating internal confidence.

Related Party Transactions

• The transaction involves the CEO, Edward Pershing, acquiring a convertible note from Provectus Biopharmaceuticals, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock upon conversion of the note and preferred stock.
• Management: Increased alignment of the CEO's financial interests with the company's performance.

Next Steps

• The 8% unsecured convertible promissory note may be voluntarily converted by the reporting person into Series D-1 Preferred Stock at any time.
• The note will automatically convert into Series D-1 Preferred Stock on October 23, 2026.
• Any Series D-1 Preferred Stock held will automatically convert into Common Stock on June 26, 2026, or earlier if converted voluntarily.

Key Dates

Recommendation

The CEO's direct investment in the company through a convertible note signals strong insider confidence, which is typically a positive catalyst for stock performance, especially in smaller-cap biotech firms. This action suggests management believes the company's current valuation is attractive and future prospects are strong.

Keywords

Provectus Biopharmaceuticals, PVCT, Edward Pershing, Insider Transaction, Form 4, Convertible Note, Series D-1 Preferred Stock, CEO, Biotechnology, Financing